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Running title: β-Dystroglycan Shift in GMPPB dystrophies
4ABSTRACT
Background Defects in glycosylation of α-dystroglycan (α-DG) cause autosomal 
recessive disorders with wide clinical and genetic heterogeneity, with phenotypes
ranging from congenital muscular dystrophies to milder limb girdle muscular
dystrophies. Patients show variable reduction of immunoreactivity to antibodies
specific for glyco-epitopes of α-DG on muscle biopsy.  Recessive mutations in 18 
genes, including GDP-mannose Pyrophosphorylase B (GMPPB), have been reported
to date. With no specific clinical and pathological handles, diagnosis requires parallel
or sequential analysis of all known genes.
Methods We describe clinical, genetic and biochemical findings of 21 patients with
GMPPB-dystroglycanopathy.
Results We report 8 novel mutations and further expand current knowledge on
clinical and muscle MRI features of this condition. In addition, we report a consistent
shift in the mobility of β-DG on western blot analysis of all patients analysed by this 
mean. This was only observed in GMPPB patients in our large dystroglycanopathy
cohort. We further demonstrate that this mobility shift in GMPPB patients was due to
abnormal N-linked glycosylation of β-DG.   
Conclusions Our data demonstrate that a change in β-DG electrophoretic mobility in 
patients with dystroglycanopathy is a distinctive marker of the molecular defect in
GMPPB.
5INTRODUCTION
Dystroglycanopathies are clinically and genetically heterogeneous muscular
dystrophies caused by defective glycosylation of α-dystroglycan (α-DG) (1).  
Phenotypes range from severe congenital onset muscular dystrophies (CMD), often
associated with brain and eye defects (such as Walker Warburg Syndrome and
Muscle-eye-brain disease), to milder adult onset limb girdle muscular dystrophies
(LGMD). The dystroglycan complex is encoded by the DAG1 gene and translated as
a propeptide proteolytically cleaved into α and β subunits.  α-DG is an extracellular 
peripheral protein that undergoes extensive N- and O-linked glycosylation. The
posttranslational modifications are essential for the interactions of α-DG with 
extracellular proteins, such as laminin-2 (LAMA2), nidogen, agrin, perlecan, neurexin,
pikachurin and slit (1). β-DG is a transmembrane protein, with a single 
transmembrane region, three N-linked glycosylation sites, numerous potential
phosphorylation sites and a proline enriched cytoplasmic tail. The dystroglycan
subunits are non-covalently associated at the membrane and connect the extracellular
matrix to the cytoskeleton acting as a cell adhesion receptor and as a player in cell
adhesion-mediated signalling and cell polarity.
Primary dystroglycanopathies with mutations in DAG1 gene remain extremely rare
(2-4). On the other hand, the class of secondary dystroglycanopathies is ever-
growing, with mutations in 18 genes reported to date (1,5). Suspicion of a
dystroglycanopathy is based on clinical, brain imaging and pathological findings (6).
Since mutations in all genes involved affect glycosylation modifications on α-DG, 
largely but not exclusively represented by O-linked glycans, muscle biopsies show
alterations in labelling with antibodies against α-DG glyco-epitopes (such as IIH6 and 
VA4-1).  The IIH6 epitope specifically recognises the G-domain binding site of α-DG 
6and indeed the use of blocking antibodies against IIH6 decouples this protein from
laminin in cultured myoblasts (7). Quantitative or qualitative changes of β-DG 
immunolabelling are generally not present and reduction of laminin α2 may be 
observed (8). Diagnosis is established by identification of pathogenic mutations in
one of the known dystroglycanopathy genes. Some of these genes (such as FKTN or
POMGnT1) more commonly cause CMD, while others (in particular FKRP) show a
wider phenotypic spectrum, with LGMD being the most prevalent phenotype.
However, since no firm genotype-phenotype correlations have been demonstrated and
there are no specific clinical or pathological markers to guide molecular
investigations, the diagnosis must be achieved through the analysis of a large panel of
genes.
Guanosine diphosphate mannose (GDP-mannose) pyrophosphorylase B (GMPPB), or
mannose-1-phosphate guanyltransferase beta, is a cytoplasmic protein that catalyses
the formation of GDP-mannose from mannose-1-phosphate and GTP. GDP-mannose
is a key substrate for 4 distinct glycosylation pathways including N-glycosylation and
O-mannosylation. Our group first described mutations in the GMPPB gene in
patients with dystroglycanopathy (8). To date, 57 patients with GMPPB gene
mutations have been reported. Phenotypes range from CMD to LGMD (LGMD2T),
including isolated rhabdomyolysis and congenital myasthenic syndrome (CMS) with
associated muscular dystrophy (9-19). Major inter and intrafamilial clinical variability
is now recognised. Apart from the observation of neuromuscular junction
abnormalities in a subset of patients with GMPPB gene mutations, no other findings
distinguish this condition from other dystroglycanopathies.
Here we describe novel clinical, pathological and genetic findings on a large cohort of
patients with GMPPB gene related muscular dystrophies (GMPPB-MD), further
7expanding our knowledge on this emerging condition.  A change in β-DG 
electrophoretic mobility was observed in the western blot of all biopsies analysed
from this cohort, which was secondary to a defect in its N-glycosylation. This finding
represents a novel and distinctive indicator of a molecular defect in the GMPPB gene
and a biomarker for GMPPB-MD.
METHODS
Patients
This study was approved by the Health Research Authority, NRES Committee East of
England – Hatfield (REC 13/EE/0398). Informed consent was obtained from patients
and parents, where appropriate. Patients were selected among those referred to the
Nationally Commissioned Highly Specialised Service (HSS) for CMD in London and
LGMD in Newcastle upon Tyne with suspicion of dystroglycanopathy based on
clinical, MRI or pathological ground.  Reduction or absence of α-DG 
immunolabelling in patients who underwent muscle biopsy was the main criteria for
activation of genetic analysis. In five patients (N8-12), genetic analysis of GMPPB
was targeted prospectively following observation on the β-DG electrophoretic 
abnormality hereby reported. Clinical, muscle and brain MRI data, serum creatine
kinase (CK) levels, neurophysiology and muscle pathology findings were obtained by
retrospective analysis of clinical notes of patients included in the study. Cardiac
function was investigated with echocardiogram and electrocardiogram. Respiratory
function was assessed by annual spirometry. The cohort included 15 novel patients
(N1-N14) and 6 previously reported individuals for whom we now report novel
muscle MRI and protein data (patients 3, 7, 9-11 reported by Belaya et al., 2015;
patient N1 by Carss et al., 2013) (8,12).
8Genetic Analysis
Full gene sequencing of the GMPPB gene (Ref Sequence NM013334.2) was
performed by Sanger sequencing and/or next generation panel sequencing at the
Viapath Molecular Laboratory at Guys and St Thomas’ Trust, London as part of the
HSS for CMD (details available upon requests). In addition to the GMPPB gene,
analysis of the POMT1, POMT2, POMGNT1, FKRP, FKTN, LARGE, ISPD, GMPPB,
B3GALNT2, B3GNT1, COL4A1, DAG1, POMK, DPM1, DPM2, DPM3, GTDC2 and
TMEM5 genes was also performed. In silico analysis of novel variants was performed
using the Alamut mutation analysis software (Interactive Biosoftware, v1.5
http://www.interactivebiosoftware.com/). Novel variants were considered as likely
pathogenic if affecting a moderate to highly conserved nucleotide, or a highly
conserved residue, or if the resulting physiochemical difference between the wild-type
and mutant amino acid was at least moderate. Affected and unaffected family
members, where available, underwent segregation analysis to confirm phase of the
variants identified and co-segregations with disease in the family.
Protein analysis
Protein analysis by immunohistochemistry and Multiplex Western blot was arranged
with a battery of 35 diagnostic antibodies for LGMD, CMD and overlapping disorders
including α-DG (IIH6, a kind gift of Dr. Kevin Campbell, University of Iowa, USA), 
β-DG and laminin-α2 (80 and 300 kDa fragments) as previously described (20- 21).   
Deglycosylation Experiment
Proteins were extracted from muscle samples as previously described (22) and some
incubated with N-Glycanase (Glyco, Prozyme) according to manufacturer's protocol.
Immunoblotting of muscle protein lysates non-treated and treated was performed as
previously described (22).
9RESULTS
GMPPB gene mutations in novel GMPPB-MD patients
We identified 14 unrelated patients with pathogenic GMPPB gene mutations (Table
1). We identified 8 novel variants, one in homozygosity in 3 families. Six patients
carried the recurrent p.Asp27His variant and two the p.Arg287Gln mutation.
Phenotypic analysis of novel GMPPB-MD patients
Five patients (N1, 3A-3B, 14-15) had a diagnosis of CMD while 8 presented with an
LGMD phenotype (N2, 4-5, 8-12) (table 1). Patient N6, at age 13 years, had raised
CK and intellectual disability (ID) with speech delay but no muscle weakness, while
patient N7 at age 5 years only showed raised CK but completely normal intellect and
no speech delay. Median age of onset in LGMD patients was mid-late 30s (range 1-
49 years). All patients were ambulant at last assessment (median 31 years), and 11/15
were able to run. Pattern of muscle involvement was proximal>distal, affecting lower
limbs more than upper limbs. Calf hypertrophy was noted in 4 patients. Variable
degree of speech and learning delay was observed in 5 patients with CMD and 2 with
LGMD . Three patients had microcephaly and one patient congenital cataract. One
patient had ocular myasthenia. Neurophysiology showed myotonic discharges in two
siblings (N3A-B). No patient had cardiac or respiratory insufficiency.
Muscle MRI imaging
Muscle MRI images were available for 5 novel patients (N2, 6, 10-12) and 2
previously reported cases (patient P1, Carrs et al; 2013 and Case 3, Belaya et al.,
2015) (figure 1). MRI of patient N2 showed symmetric STIR signalling abnormality
of gastrocnemious and soleus, and swelling of medial head of the gastrocnemius
(figure 1A). A general reduction of thigh muscle bulk, with increase in muscle fat in
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particular in the posterior compartment was found at age 9 in a CMD patient reported
by Carrs et al, and the repeated scan 5 years later showed overall stable appearance
(figure 1C and 1D). MRI scan of patient N6 showed very symmetric mild fatty
streaking within both semitendinosus and sartorius muscles (figure 1B). Patients
N10,N11, N12 and Case 3 of Belaya et al (2015) showed symmetrical posterior more
than anterior involvement, more in upper than lower leg, atrophy of the rectus
femoris, gastrocnemius (medial head more than lateral), tibialis anterior and peroneal
muscles, with relative sparing of vastus intermedius, sartorius and gracilis muscles
(figure 1E-1F and 1H). Spinal MRI in patient N9 showed selective atrophy of erector
spinae and paraspinal muscles (data not shown).
Protein analysis
Muscle biopsies of all patients displayed a variable range of myopathic or dystrophic
changes and patchy expression of α-DG.  Laminin-α2 showed mild reduction of 
labelling in some but not in all cases.  Immunolabelling of β-DG was normal in all 
patients on sections (data not shown). Western blot analysis consistently showed a
slightly higher mobility (reflected as a slightly lower molecular mass) of β-DG in 
12/12 patients GMPPB samples analysed, often seen together with a reduction of
laminin-α2 (80 kDa fragment) (figure 2A and 2B). The mobility shift of β-DG was 
not observed in samples from patients with dystroglycanopathy caused by mutations
in other genes including FKRP (34 patients), POMGnT1 (3 patients), POMT1 (2
patients), POMT2 (2 patients), ISPD (2 patients) and B3GALNT2 (2 patients; see
figure 2B and not shown). β-DG harbors 3 N-linked glycosylation sites.  Since the 
conversion of mannose-1-phosphate and GTP to GDP-mannose catalyzed by GMPPB
is a common step for both O- and N-linked glycosylation, we proceeded to assess
whether the mobility shift of β-DG was due to a defect in N-glycosylation.  N-
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glycanase treated muscle tissue of healthy control and GMPPB-MD patients showed
similar electrophoretic mobility (figure 2C). β-DG molecular mobility was increased 
in N-glycanase treated GMPPB samples compared to untreated ones (supplemental
figure 1). These results suggest that the observed mobility shift in GMPPB-MD
patients is secondary to the defective Dystroglycan N-glycosylation.
DISCUSSION
Mutations in the GMPPB gene cause a broad spectrum of increasingly prevalent
dystroglycanopathies. Phenotypic analysis of the families reported here confirms and
further expands our knowledge of GMPPB associated phenotypes. In particular, our
data confirms the prevalence of LGMD phenotype in association with GMPPB gene
mutations and expands the phenotypic spectrum by describing a patient with mental
retardation and raised CK only at age 13 years. We confirm a high frequency of
learning and speech delay, relatively high occurrence of microcephaly in CMD
patients but lack of major cardiac and respiratory involvement. The cause and
significance of the myotonic discharges observed in the 2 siblings from a
consanguineous family is unclear. However, as this has never been reported in
patients with GMPPB gene mutations before, it might represent an additional
uncharacterised condition present in this consanguineous family. Patterns of muscle
involvement on MRI in LGMD patients were strikingly similar, with symmetrical
posterior>anterior involvement and specific muscle atrophies in particular of erector
spinae, rectus femoris and peroneal muscles. This pattern is similar to that reported by
Oestergaard et al. (16), and partly resembles patterns observed in LGMD2A and to a
lesser degree LGMD2I (23). We also observed no/minimal muscle MRI involvement
in patients with milder muscle phenotype.
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Including this cohort, GMPPB gene mutations have so far been described in 72
patients. Review of clinical data for published patients evidenced LGMD as the most
common phenotypic presentation of GMPPB-DG (42 patients, 58%). CMD (18
patients, 25%), and CMS-like conditions (8 patients, 11%) are less common, although
clinical and electrophysiological features of CMS were also reported in 12 LGMD
patients (27%). Milder phenotypes, such as isolated ID, rhabdomyolysis, metabolic
myopathy or isolated hyperCKaemia were observed in 4 individuals, although these
patients could develop further symptoms with age. Among CMD patients, CMD-MR
was the most common subtype (9/18 patients), but CMD-CRB and CMD-MEB were
also reported. Average age at onset in LGMD and in CMS was late teens and early
20s, respectively. A variable degree of learning difficulties was observed in patients
with any type of presentations, including 23% of LGMD patients and great majority
of CMD patients, and in at least 3 patients this represented the main clinical feature,
in association with no or fairly minimal muscle weakness at age 13, 14 and 36 years
and CK in the range of 3000-4000 IU/L (present cohort; 10 and 12). Overall, these
data show that GMPPB mutations are more likely to cause LGMD or LGMD/CMS
overlap syndromes rather than congenital onset conditions and some degree of ID is a
frequent observation. Considering that all cohorts so far come from groups with
predominant expertise in muscular dystrophies, the observation that hyperCKaemia,
isolated or associated with rhabdomyolysis or ID, can be predominant features in
GMPPB related conditions suggest that the prevalence of this condition could be
higher if these unusual phenotypes were systematically studied for the involvement of
this gene.
A total of 42 GMPPB mutations are known to date, all but 7 being missense changes.
Two variants are more common, with the p.Asp27His and p.Arg287Gln mutations
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representing 24% and 10% of all alleles. Of note, a further 7% of alleles also affected
residue 287 (c.859C>T p.(Arg287Trp)), but mostly found in the LGMD patients (5/7
patients). Our analysis indicates additional hotspots, such as at residue Pro32, Pro103
and Arg185. We have reported a novel in frame 4 nucleotide deletion, occurring in
homozygosity in 3 apparently unrelated families, leading to deletion of residue 270
and substitution in position 271. Interestingly, mutations affecting residues between
Pro241 to Asn271 were also frequent. Previous reports indicated some genotype-
phenotype correlations, with the two common variants p.Asp27His and p.Arg287Gln
being associated with LGMD and CMD, respectively. Our data further confirm this
finding, with the p.Asp27His mutation being only present in LGMD or asymptomatic
patients from our cohort (table 1). The distribution of mutations does not appear to
correlate with clinical severity and we did not identify any genotype phenotype
correlation with nonsense/splice site mutations.
Dystroglycanopathies are mostly diagnosed based on the depletion of IIH6
immunostaining but no pathology biomarkers specific for each genetic subtype is
known. The increasing knowledge of the prevalence of specific genetic subtypes and
their association with variable clinical presentations helps with targeted gene analysis
(24-25). However, the ever-increasing number of genes associated with
dystroglycanopathies makes genetic diagnosis rather challenging and despite major
advances, parallel gene sequencing of all known genes is still the most validated
diagnostic approach. Furthermore, a number of patients remain without genetic
confirmation and novel genes might be more common than expected. We have now
identified a novel and distinctive marker, a β-DG mobility shift on WB that, in 
combination to abnormal labelling of IIH6, can guide further genetic analysis of
dystroglycanopathies. Our data showed 100% specificity and sensitivity, as all
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patients with this biomarker had a diagnosis of GMPPB-MD; while this was a
universal feature in GMPPB patients, the shift was more evident in some patients than
others, and did not correlate with age. Of note, 5 patients were identified based on
retrospective review of WB analysis of genetically undiagnosed dystroglycanopathy
patients and observation of the typical β-DG mobility.  We have not identified a 
similar mobility shift before in analysis of 45 patients with at least 6 genetically
proven dystroglycanopathies (figure 2; 26-27). Furthermore, we did not see the
mobility shift in additional genetically undiagnosed dystroglycanopathy patients
tested with our gene panel. In view of this, we suggest that this β-DG mobility shift in 
combination with abnormal immunolabelling of IIH6 could be considered a strong
indicator for GMPPB-MD, which can therefore be used to directly guide the genetic
diagnosis. WB analysis of patient fibroblasts from this study and from Carss et al. (8)
showed that β-DG was normal compared to controls (data not shown) suggesting that 
the posttranslational event affected by mutations in the GMPPB gene may be tissue
specific. GMPPB is a key enzyme for both N- and O- glycosylation. Therefore we
hypothesised that the observed mobility shift of β-DG was due to abnormal N-linked 
glycosylation by means of a defective GMPPB protein. This was confirmed by
observing deglycosylated bands of identical size in both controls and patients after N-
glycanase treatment (figure 2C). GMPPB catalyzes the synthesis of GDP-mannose
from GTP and mannose-1-phosphate. GDP-mannose is the substrate of cytosolic
mannosyltransferases required for the synthesis of the core N-glycan structure, and it
is required for the synthesis of Dol-P-Man in the ER membrane. Dol-P-Man synthesis
is catalyzed by the DPM synthase complex, consisting of DPM1, DPM2, and DPM3.
Dol-P-Man is the mannose donor required for all four mannosylation reactions that
occur in the ER: O-mannosylation, C-mannosylation, N-glycosylation, and
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glycosylphosphatidylinositol-anchor formation. As ß-Dystroglycan contains three N-
linked glycosylation site (28), we infer that the deficiency of GMPPB results in
defective N-glycosylation of this crucial muscle protein. Of note, patients with
GMPPB gene mutations, when tested, showed normal routine diagnostic screening for
CDG (8).
In conclusion, this is the first report of a biochemical marker of a specific genetic type
of dystroglycanopathies. Importantly, we demonstrate that mutations in GMPPB
affect glycosylation of α as well of β-DG. Detection of changes in β-DG 
electrophoretic mobility in muscle biopsies has the potential to refine the laboratory’s
diagnostic capabilities and ultimately improve clinical care. The defective N-
glycosylation of β-DG could potentially contribute to some of the unique features 
observed in GMPPB patients, including defective neuromuscular junction signal
transmission, but this will require further studies.
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Figure 1: Muscle MRI images of patients with GMPPB gene mutations.
Images A, E,F and H show the pattern of muscle involvement in 4 patients with
LGMD (Pt N2, 10,11 and 12). Note the symmetrical posterior >anterior involvement
in upper legs, with atrophy of the rectus femoris with sparing of vastus intermedius,
sartorius and gracilis muscles in E, F and H. A variable degree of atrophy of the
gastrocnemius tibialis anterior and peroneal muscles is noted in the lower legs (E,F
and H). Image 1G shows a similar pattern of muscle involvement in a CMS patient
with LGMD weakness (Case 3 Belaya et al 2015). Symmetrical mild fatty streaking in
semitendinosus and sartorius muscles is noted in image B relative to patient N6 with
ID. Reduction of thigh muscle bulk and increase in muscle fat in the posterior
compartment is evidenced in 2 sequential studies for at age 9 (D) and 14 years (E) for
a CMD patient (Patient P1, Carss et al, 2013).
Figure 2: Western blot analysis of patients with GMPPB gene mutations and
other genetically proven dystroglycanopathies
A) Consistent lower mobility shift of β-DG in 6 patients with GMPPB gene
mutations. B) The shift is not observed in samples from 2 patients with mutations in
FKRP and one patient with mutations in POMGnT1 gene. C) Bands of equal size are
observed in control and patients after N-Glycanase treatment.
Supplemental Figure 1: Western blot analysis of N-glycanase treated muscle
tissue of control and GMPPB-MD patients
Lane 1-4: Western blot analysis of muscle tissue of healthy control and patients
without N-glycanase treatment (-); lane 5-8: Western blot analysis of muscle tissue of
healthy control and patients after N-glycanase treatment (+).
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Table 1: Clinical and genetic characteristics of 15 novel patients
Pt Sex Age Phenotype onset(years)
CK








findings Mutation1 Mutation 2












































































Run N NA c.79G>Cp.(Asp27His)
c.859C>T
p.(Arg287Trp)










N7 M 5 - - 1200 - N Run N NA c.79G>Ap.(Asp27His)
c. 988G>A
p.(Val330Ile)















Legend: CK creatine kinase, F female, M male, CMD Congenital muscular dystrophy, , LGMD limb girdle muscular dystrophy, TA Achilles
tendons, MC, microcephaly, N normal, NA not available, LL lower limbs, UL upper limbs, > more. Novel mutations are indicated in bold.






Run N NA c.79G>Ap.(Asp27His)
c.87C>A
p.(Cys29Ter)































































NA Torticollis, atrialseptal defect
c.1069G>A
p.(Val357Ile)
c.1081G>A
p.(Asp361Asn)



